RESUMEN
BACKGROUND: PD psychosis is often associated with cognitive impairment, including dementia, and involves dopaminergic, serotonergic, and cholinergic mechanisms. OBJECTIVE: To evaluate the differential effect of the antipsychotic pimavanserin, a selective serotonin 2A receptor inverse agonist, in PD psychosis patients with versus without cognitive impairment and in those receiving versus not receiving cognitive-enhancing medications. METHODS: Data from the pivotal randomized clinical trial of pimavanserin for PD psychosis were stratified by (1) screening MMSE score as cognitively impaired (21-24) versus unimpaired (≥25) and (2) concomitant use versus nonuse of cognitive-enhancing medications. The primary outcome measure was change in the PD-adapted Scale for the Assessment of Positive Symptoms. RESULTS: Mean (pimavanserin vs. placebo) change from baseline was larger in the cognitively impaired (n = 50; -6.62 vs. -0.91; P = 0.002) versus the cognitively unimpaired (n = 135; -5.50 vs. -3.23; p = 0.046) group. The comparable change was -6.04 versus -2.18 (P = 0.012) and -5.66 versus -3.15 (P = 0.041) in patients treated (n = 69) and not treated (n = 116) with concomitant cognitive-enhancing medication. Pimavanserin was similarly tolerated across all cognitive groups with no additional safety concerns identified. Overall adverse event rates were comparable across the concomitant cognitive-enhancing medication groups; however, rates of serious adverse events and discontinuations attributed to adverse events were increased in patients taking cholinesterase inhibitors. CONCLUSIONS: The antipsychotic effect of pimavanserin is robust in PD patients with cognitive impairment and may be enhanced by concomitant cognitive-enhancing medication use. Future prospective studies are needed to confirm these preliminary findings. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Asunto(s)
Antipsicóticos/uso terapéutico , Trastornos del Conocimiento/tratamiento farmacológico , Nootrópicos/uso terapéutico , Enfermedad de Parkinson/complicaciones , Piperidinas/uso terapéutico , Trastornos Psicóticos/tratamiento farmacológico , Trastornos Psicóticos/etiología , Urea/análogos & derivados , Anciano , Anciano de 80 o más Años , Trastornos del Conocimiento/etiología , Método Doble Ciego , Femenino , Humanos , Masculino , Escala del Estado Mental , Persona de Mediana Edad , Resultado del Tratamiento , Urea/uso terapéuticoRESUMEN
BACKGROUND: Molecular imaging has proven to be a powerful tool to elucidate degenerated paths in a wide variety of neurological diseases and has not been systematically studied in hereditary spastic paraplegias. OBJECTIVES: To investigate dopaminergic degeneration in a cohort of 22 patients with hereditary spastic paraplegia attributed to SPG11 mutations and evaluate treatment response to l-dopa. METHODS: Patients and controls underwent single-photon emission computed tomography imaging utilizing 99m Tc-TRODAT-1 tracer. A single-blind trial with 600 mg of l-dopa was performed comparing UPDRS scores. RESULTS: Reduced dopamine transporter density was universal among patients. Nigral degeneration was symmetrical and correlated with disease duration and motor and cognitive handicap. No statistically significant benefit could be demonstrated with l-dopa intake during the trial. CONCLUSION: Disruption of presynaptic dopaminergic pathways is a widespread phenomenon in patients with SPG11 mutations, even in the absence of parkinsonism. Unresponsiveness to treatment could be related to postsynaptic damage that needs to be further investigated.
Asunto(s)
Antiparkinsonianos/uso terapéutico , Levodopa/uso terapéutico , Mutación/genética , Trastornos Parkinsonianos , Proteínas/genética , Adulto , Encéfalo/diagnóstico por imagen , Encéfalo/efectos de los fármacos , Trastornos del Conocimiento/etiología , Estudios de Cohortes , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Femenino , Humanos , Masculino , Trastornos Mentales/etiología , Persona de Mediana Edad , Pruebas Neuropsicológicas , Compuestos de Organotecnecio/farmacocinética , Trastornos Parkinsonianos/complicaciones , Trastornos Parkinsonianos/diagnóstico por imagen , Trastornos Parkinsonianos/tratamiento farmacológico , Trastornos Parkinsonianos/genética , Método Simple Ciego , Estadísticas no Paramétricas , Tomógrafos Computarizados por Rayos X , Tomografía Computarizada de Emisión de Fotón Único , Tropanos/farmacocinética , Adulto JovenRESUMEN
Nonmotor symptoms (NMSs) in Parkinson's disease (PD) have become increasingly recognized as major determinants of quality of life across cultures worldwide. Behavioral symptoms include dementia, depression, anxiety, apathy, and fatigue. Somatic symptoms include hypotension, constipation, diaphoresis, and pain. However, somatic symptoms may also be intrinsic, such as dementia, and iatrogenic, such as compulsive disorders. The authors address some of the more common disorders, yet few have been the target of clinical trials.
Asunto(s)
Síntomas Conductuales/etiología , Trastornos del Conocimiento/etiología , Enfermedad de Parkinson/complicaciones , Enfermedades de la Piel/etiología , Trastornos del Sueño-Vigilia/etiología , Fatiga/etiología , Humanos , Dolor/etiología , Enfermedad de Parkinson/psicologíaRESUMEN
The authors studied the effects of rasagiline on cognition in a sample of 50 nondemented patients with mild to moderate Parkinson's disease (PD) using a double-blind, placebo controlled design. Cognition and motor symptoms were assessed at baseline and after 6 months of receiving either rasagiline or placebo. Participants receiving rasagiline showed improvement in their motor symptoms of PD compared to participants receiving placebo. No significant changes in performance on neuropsychological measures of cognition were observed between the groups. Rasagiline is an effective treatment for the motor symptoms of PD. Rasagiline did not appear to affect cognition during this 6-month study.
Asunto(s)
Antiparkinsonianos/uso terapéutico , Cognición/efectos de los fármacos , Indanos/uso terapéutico , Inhibidores de la Monoaminooxidasa/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/psicología , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Nootrópicos/uso terapéutico , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
BACKGROUND: Few studies have systematically investigated the association between PARKIN genotype and psychiatric co-morbidities of Parkison's disease (PD). PARKIN-associated PD is characterized by severe nigral dopaminergic neuronal loss, a finding that may have implications for behaviors rooted in dopaminergic circuits such as obsessive-compulsive symptoms (OCS). METHODS: The Schedule of Compulsions and Obsessions Patient Inventory (SCOPI) was administered to 104 patients with early-onset PD and 257 asymptomatic first-degree relatives. Carriers of one and two PARKIN mutations were compared with noncarriers. RESULTS: Among patients, carriers scored lower than noncarriers in adjusted models (one-mutation: 13.9 point difference, P = 0.03; two-mutation: 24.1, P = 0.001), where lower scores indicate less OCS. Among asymptomatic relatives, a trend toward the opposite was seen: mutation carriers scored higher than noncarriers (one mutation, P = 0.05; two mutations, P = 0.13). CONCLUSIONS: First, a significant association was found between PARKIN mutation status and obsessive-compulsive symptom level in both PD and asymptomatic patients, suggesting that OCS might represent an early non-motor dopamine-dependent feature. Second, irrespective of disease status, heterozygotes were significantly different from noncarriers, suggesting that PARKIN heterozygosity may contribute to phenotype. © 2014 International Parkinson and Movement Disorder Society.
Asunto(s)
Predisposición Genética a la Enfermedad , Mutación/genética , Trastorno Obsesivo Compulsivo/genética , Enfermedad de Parkinson/genética , Ubiquitina-Proteína Ligasas/genética , Adulto , Edad de Inicio , Anciano , Femenino , Pruebas Genéticas , Genotipo , Heterocigoto , Humanos , Masculino , Persona de Mediana Edad , Trastorno Obsesivo Compulsivo/etiología , Enfermedad de Parkinson/complicacionesRESUMEN
Apathy is a common feature of neurodegenerative disorders but is difficult to study in a clinical trial setting due to practical and conceptual barriers. Principal challenges include a paucity of data regarding apathy in these disorders, an absence of established diagnostic criteria, the presence of confounding factors (eg, coexisting depression), use of concomitant medications, and an absence of a gold-standard apathy assessment scale. Based on a literature search and ongoing collaboration among the authors, we present recommendations for the design of future clinical trials of apathy, suggesting Alzheimer disease and Parkinson disease as models with relevance across a wider array of neuropsychiatric disorders. Recommendations address clarification of the targeted study population (apathy diagnosis and severity at baseline), confounding factors (mood/cognition, behavior, and treatment), outcome measures, study duration, use of comparators and considerations around environment, and the role of the caregiver and patient assent. This review contributes to the search for an optimal approach to study treatment of apathy in neuropsychiatric disorders.
Asunto(s)
Apatía , Ensayos Clínicos como Asunto , Proyectos de Investigación , Enfermedad de Alzheimer/psicología , Depresión/diagnóstico , Depresión/psicología , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/psicología , Humanos , Masculino , Enfermedad de Parkinson/complicacionesAsunto(s)
Levodopa , Enfermedad de Parkinson , Antiparkinsonianos , Progresión de la Enfermedad , HumanosRESUMEN
Jaw clonus is an uncommon pathological reflex thought to indicate corticospinal tract dysfunction above the Vth cranial nerve. It is useful as a sign of upper motor neuron dysfunction above the spinal cord. One theory of self excitation posits an inverse and linear relationship between clonus frequency and the length of the reflex arc, to explain the higher frequency of clonus in the ankles than the wrist. Only two previous cases of jaw clonus have been published. One of these plus the present case suggest that an inverse and linear relationship is not correct.
Asunto(s)
Maxilares/fisiopatología , Enfermedad de la Neurona Motora/diagnóstico , Mioclonía/patología , Mioclonía/fisiopatología , Anciano de 80 o más Años , Humanos , Masculino , Enfermedad de la Neurona Motora/patología , Enfermedad de la Neurona Motora/fisiopatología , Reflejo , Caminata/fisiologíaRESUMEN
BACKGROUND: RECOVER (NCT00474058), a double-blind, placebo-controlled trial in patients with Parkinson's disease (PD) and unsatisfactory early-morning motor symptom control, demonstrated significant improvements with rotigotine in early-morning motor function (Unified Parkinson's Disease Rating Scale [UPDRS] III), and nocturnal sleep disturbances (modified Parkinson's Disease Sleep Scale [PDSS-2]), and improvements in nonmotor symptoms (NMS; Non-Motor Symptom Scale [NMSS]). METHODS: Post hoc analyses investigated the correlation between motor symptom and NMS severity in PD by evaluating associations between UPDRS III and both NMSS and PDSS-2 scores. Categories were defined for UPDRS III, NMSS, and PDSS-2 total scores; analyses were conducted for the full analysis set (n = 267). RESULTS: There was a trend toward increasing PDSS-2 and NMSS total and domain scores with increasing UPDRS III category at baseline and end of maintenance (EoM). Pearson correlation coefficients between UPDRS III and both NMSS and PDSS-2 total and domain scores were r = 0.12-0.44 (r(2) = 0.01-0.19) at baseline, r = 0.05-0.38 (r(2) = 0.00-0.14) at EoM, and r = -0.02-0.36 (r(2) = 0.00-0.13) for change from baseline to EoM. CONCLUSION: There was only a small correlation between severity of early-morning motor symptoms and overall burden of NMS and nocturnal sleep disturbances in RECOVER, suggesting that motor symptoms and NMS originate, at least partly, from distinct pathophysiological pathways.
Asunto(s)
Antiparkinsonianos/uso terapéutico , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/tratamiento farmacológico , Trastornos del Sueño-Vigilia/epidemiología , Tetrahidronaftalenos/uso terapéutico , Tiofenos/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos del Sueño-Vigilia/etiologíaRESUMEN
INTRODUCTION: Psychotic symptoms in people with Parkinson's disease (PD) have attracted increasing. Recommendations on treating psychosis often fail to take into account what psychotic symptoms require treatment, which has been complicated by the increasing number of reports documenting the frequency of 'minor' hallucinations. AREAS COVERED: This article focuses both on the phenomenology of psychotic symptoms and their management. EXPERT OPINION: Understanding the nature and implications of the types of psychotic symptoms in PD is the key to proper treatment. Evidence and experience-based data on the effect of anti-psychotic medications will be reviewed and how the various clinical settings should determine the treatment approach. The evidence base consists of all reported blinded trials recorded in PubMed and the experience-based studies are those chosen by the author from PubMed as illustrative. Specific recommendations for the treatment of psychosis will be listed for specific situations. Pimavanserin is the first-line choice for mild symptoms; quetiapine for symptoms that require improvement in a short period and clozapine for urgent problems or those which fail the other approaches.
Psychotic symptoms are common in PD, affecting the majority of patients by the time of death. 'Minor hallucinations' rarely require treatment but formed hallucinations and delusions often do. The vast majority of patients requiring treatment are on medications for PD motor problems. Some patients can be treated with reduction of psychoactive medications that are unrelated to PD, and some may tolerate reductions in PD medications without intolerable worsening of motor function. The remainder require treatment with medications that reduce psychotic symptoms, which include cholinesterase inhibitors, clozapine, pimavanserin, and possibly quetiapine and electroconvulsive therapy. Only clozapine and pimavanserin have unequivocal evidence for efficacy and motor tolerance. Data will be reviewed in support of each of these medications will be reviewed and pragmatic suggestions based on a large experience on when each might be used, and in what order they may be tried if initial approaches fail.
Asunto(s)
Antipsicóticos , Clozapina , Enfermedad de Parkinson , Trastornos Psicóticos , Humanos , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/complicaciones , Trastornos Psicóticos/tratamiento farmacológico , Trastornos Psicóticos/etiología , Fumarato de Quetiapina/uso terapéutico , Clozapina/uso terapéutico , Urea/uso terapéutico , Antipsicóticos/uso terapéuticoRESUMEN
The antiphospholipid syndrome (APS) is defined by the presence of antiphospholipid antibodies and related disorders, generally thromboses, miscarriages, livedo reticularis or heart valve abnormalities. It is thought to have a prevalence of about 40-50 cases per 100,000 in the general population.1 Several neurological disorders have been associated with APS, most commonly stroke, but non-stroke complications, thought due to auto- immune problems, have been noted, with chorea being the most common. Isolated toe tremor, that is, without any other neurological signs or symptoms, has not been reported. We describe a case of recurrent isolated uni- lateral toe tremor in an otherwise healthy woman with long-standing APS.
Asunto(s)
Síndrome Antifosfolípido , Dedos del Pie , Temblor , Humanos , Síndrome Antifosfolípido/complicaciones , Síndrome Antifosfolípido/diagnóstico , Femenino , Temblor/etiología , Persona de Mediana EdadRESUMEN
BACKGROUND: Parkinson's disease (PD) progresses at highly variable rates in different individuals but, in general, has a fairly stable rate of progression in each patient. In cases where the decline in cognition and behavior suddenly accelerates, we usually think of co-existent Alzheimer pathology, as most demented PD patients also have Alzheimer disease (AD) changes, although not necessarily meeting criteria for a distinct pathological diagnosis of AD. METHODS: Clinico-pathological case Results: A 75-year-old woman presented with a typical PD course including a good response to L-Dopa. Four years after diagnosis she developed a rapid decline in motor symptoms, severe cognitive fluctuations, and rapidly progressive dementia, dying within one year of the onset of the rapid progression. CONCLUSIONS: While most cases of Parkinson's disease dementia (PDD) show concomitant Alzheimer's pathology, the sudden acceleration of the disease does not necessarily indicate the presence of concomitant Alzheimer's disease.
Asunto(s)
Demencia , Progresión de la Enfermedad , Glucosilceramidasa , Enfermedad de Parkinson , Humanos , Femenino , Anciano , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/genética , Glucosilceramidasa/genética , Autopsia , Mutación , Resultado Fatal , Enfermedad de Alzheimer/genética , Encéfalo/patología , Encéfalo/diagnóstico por imagenRESUMEN
Objective: Current clinician-rated tardive dyskinesia (TD) symptom scales have not addressed the expanding clinical signs and functional impact of TD. The study objective was to develop and test the reliability of a new integrated instrument.Methods: A movement disorder neurologist devised the outline of the rating scale. A Steering Committee (5 neurologists and 2 psychiatrists) provided revisions until consensus was reached. The Clinician's Tardive Inventory (CTI) assesses abnormal movements of the eye/eyelid/face, tongue/mouth, jaw, and limb/trunk; complex movements defined as complicated movements different from simple patterned movements or postures; and vocalizations. The CTI rates frequency of symptoms from 0 to 3 (ranging from absent to constant). Functional impairments, including activities of daily living (ADL), social impairment, symptom distress, and physical harm, are rated 0-3 (ranging from unawareness to severe impact). The CTI underwent interrater and test-retest reliability testing between February and June 2022 based on videos and accompanying vignettes, which were reviewed by 2 movement disorder specialists to determine adequacy. Four clinicians rated each video/vignette. Interrater agreement was analyzed via 2-way random-effects intraclass correlation (ICC), and test-retest agreement was assessed utilizing the Kendall tau-b.Results: Forty-five video/vignettes were assessed for interrater reliability and 16 for test-retest reliability. The most prevalent movements were those of the tongue and mouth (77.8%) and jaw (55.6%). ICCs for movement frequency for anatomic symptoms were as follows: anatomic symptom summary score 0.92, abnormal eye movement 0.89, abnormal tongue/mouth movement 0.91, abnormal jaw movement 0.89, abnormal limb movement 0.76, complex movement 0.87, and abnormal vocalization 0.77; ICCs for functional impairments were as follows: total impairment score 0.92, physical harm 0.82, social embarrassment 0.88, ADLs 0.83, and symptom bother 0.92; Retests were conducted a mean (SD) of 15 (3) days later with correlation coefficients ranging from 0.66 to 0.87.Conclusions: The CTI is a new integrated instrument with proven reliability in assessing TD signs and functional impacts. Future validation study is warranted.
Asunto(s)
Trastornos del Movimiento , Discinesia Tardía , Humanos , Discinesia Tardía/inducido químicamente , Discinesia Tardía/diagnóstico , Actividades Cotidianas , Reproducibilidad de los Resultados , ConsensoRESUMEN
Electroconvulsive therapy (ECT) in Parkinson's disease has been the subject of occassional publications. Generally it has been successfully used in treating severe depression, and rare case reports describe its benefit in psychosis unresponsive to standard antipsychotic drugs. This report describes two patient with idiopathic PD and severe anxiety who responded well to ECT. ECT should be considered for PD patients with severe behavioral problems not responsive to medications.